Roopa Ramamoorthi PhD, PMP, Associate Director, Partnering and Scientific Affairs

Size: px

Start display at page:

Download "Roopa Ramamoorthi PhD, PMP, Associate Director, Partnering and Scientific Affairs"

Jasmine Roberts
8 years ago
Views:

1 Roopa Ramamoorthi PhD, PMP, Associate Director, Partnering and Scientific Affairs BIO Ventures for Global Health Sharing Innovation in the Fight Against Neglected Tropical Diseases World Intellectual Property Organization Secretariat BIO Ventures for Global Health Partnership Hub Administrator

Against Neglected Tropical Diseases World Intellectual Property

2 BIO Ventures for Global Health (BVGH) BVGH works to engage the biotechnology and pharmaceutical industry in global health R&D Connecting innovators with critical information and resources for R&D Identifying needs and facilitating collaboration to accelerate neglected tropical disease product development

critical information and resources for R&D Identifying needs and

3 What is WIPO Re:Search? Led by the World Intellectual Property Organization (WIPO) in collaboration with BIO Ventures for Global Health (BVGH) and its Members. The Consortium includes a number of the world s leading pharmaceutical companies, academic and nonprofit research institutions, governmental, and non governmental organizations. Makes intellectual property, know how and other resources available to Member researchers working in neglected tropical diseases (NTDs). Facilitates collaboration to develop new drugs, vaccines, and diagnostics

The Consortium includes a number of the world s leading pharmaceutical companies, academic and nonprofit research institutions,

4 Current WIPO Re:Search Members April 2013 McMaster Univ Univ of Calgary Merck (MSD) PATH Pfizer Seattle BioMed Univ of Washington Infectious Disease Research Institute (IDRI) California Inst of Tech Center for World Health & Medicine Alnylam Pharmaceuticals Northeastern Univ. Massachusetts General Hospital Univ of Cal San Francisco Univ of Cal Berkeley Stanford University Anacor Pharmaceuticals Univ. of Kansas Emory Univ. National Institutes of Health (NIH) Sabin Vaccine Institute Public Interest Intellectual Property Advisors (PIIPA) Mass. Inst of Technology (MIT) Walter Reed Army Inst. of Research (WRAIR) Assoc. of Univ Tech Managers (AUTM) BIO LESI McGill University US Patent & Trademark Office (USPTO) Aberystwyth University Fundacao Oswaldo Cruz (FioCruz) Tech Transfer Summit Ltd Univ. of Bamako National Inst. of Industrial Property (INPI) GALVmed Univ. of Dundee South African Medical Res. Council Centre for Malaria Diagnostics (ANDI) GlaxoSmithKline (GSK) Africa Fighting Malaria ithemba Pharmaceuticals Developing World Health Liverpool School of Tropical Medicine AstraZeneca Swiss Tropical and Public Health Institute Drugs for Neglected Diseases initiative (DNDi) Novartis Sanofi/Sanofi Pasteur Eisai Pharmaceuticals National Center for Genetic Engineering and Biotechnology (BIOTEC) Kenyan Agricultural Research Institute (KARI) Kumasi Centre for Collaborative Research (KCCR) Univ. of Buea, Cameroon Medicines for Malaria Venture (MMV) Kenya Medical Research Institute (KEMRI) Africa Inst. of Biomedical Science & Technology (AiBST) International Federation of Intellectual Property Attorneys (FICPI) International Federation of Pharma Manufacturers & Assoc. (IFPMA) Foundation for Innovative New Diagnostics (FIND) International Vaccine Institute (IVI) Theodor Bilharz Research Institute World Health Organization COHRED Indian Council for Medical Research Mahidol University Eskitis Institute at Griffith University

Massachusetts General Hospital Univ of Cal San Francisco Univ of Cal Berkeley Stanford University Anacor Pharmaceuticals Univ. of Kansas Emory Univ.

5 GSK University of Washington Collaboration Screening of preclinical candidates against malaria Brief Background: BVGH met with researchers at the University of Washington (UW) to gain an understanding of research programs and partnership needs. A researcher expressed interest in working with a pharmaceutical partner who could characterize and provide insights into development of UW compounds. UW professor was introduced to scientists at GSK. GSK s Tres Cantos Open Lab will re profile University of Washington compounds (Calcium dependent protein kinase inhibitors) for the ability to block the transmission of malaria using their assay systems. Current Status: Agreement to allow sharing of confidential information and transfer of compounds is in place.

A researcher expressed interest in working with a pharmaceutical partner who could characterize and provide insights into development of UW compounds.

6 Signed Agreements through WIPO Re:Search for Malaria Research Sharing of preclinical compound libraries for malaria drug discovery Sharing of cysteine protease inhibitors Sharing of calcium channel blockers Sharing of proteasome inhibitors Research collaboration around multi kinase inhibitors in malaria Screening preclinical candidates against malaria

Sharing of calcium channel blockers Sharing of proteasome inhibitors Research

A NEW COLLABORATIVE WEB-BASED DATABASE ARCHITECTURE FOR COMMUNITY- BASED PHARMACEUTICAL RESEARCH

A NEW COLLABORATIVE WEB-BASED DATABASE ARCHITECTURE FOR COMMUNITY- BASED PHARMACEUTICAL RESEARCH Collaborative Drug Discovery, Inc. Sean Ekins PhD, DSc. Using CDD can save time, money and improve discovery